<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f295b581-42f2-4a83-bd35-58d21fa32dda"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">CEFAZOLIN FOR INJECTION</content> safely and effectively.  See full prescribing information for <content styleCode="bold">CEFAZOLIN FOR INJECTION</content>.<content styleCode="bold">
         <footnote ID="_i4i5TtwqWzdx5vFqMOZvTtRt2">
            <content styleCode="italics">Pediatric use information is approved for B. Braun Medical’s Cefazolin for Injection and Dextrose for Injection. However, due to B. Braun Medical’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
         </footnote>
      </content>
      <br/>CEFAZOLIN for injection, for intravenous use.<br/>Initial U.S. Approval: 1973<br/>
   </title>
   <effectiveTime value="20240331"/>
   <setId root="4f3a9248-a354-4c77-bf5b-9eed38f00219"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="829274633" root="1.3.6.1.4.1.519.1"/>
            <name>WG Critical Care, LLC</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="9aacbaae-6c22-46c0-8976-71f9f2dc77f5"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240329"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="44567-840" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefazolin</name>
                        <formCode code="C42974" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefazolin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="P380M0454Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFAZOLIN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IHS69L0Y4T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFAZOLIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="CNTM">
                           <quantity>
                              <numerator unit="1" value="0"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2LQ0UUW8IN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NATURAL LATEX RUBBER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="44567-840-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="25"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="44567-840-25" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230518"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA211413" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230518"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="44567-845" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefazolin</name>
                        <formCode code="C42974" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefazolin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="g" value="3"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="P380M0454Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFAZOLIN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="IHS69L0Y4T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFAZOLIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="CNTM">
                           <quantity>
                              <numerator unit="1" value="0"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2LQ0UUW8IN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NATURAL LATEX RUBBER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="44567-845-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="25"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="44567-845-25" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240510"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA211413" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240510"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_97ae3cb1-139e-4ee1-8cbc-450b12bbbf9f">
               <id root="c9b6af28-1763-4c11-bcdb-32e3b7529dcd"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240329"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <paragraph>Dosage and Administration (2.1)	                                                           3/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_95548718-ec0a-4e63-8a6a-aa805d379056">
               <id root="7b268067-2dd9-438f-8a29-35f2a4062313"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20230518"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cefazolin for Injection is a cephalosporin antibacterial indicated for perioperative prophylaxis in adult patients (1.1).</paragraph>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and other antibacterial drugs, Cefazolin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.2)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_d8b785f4-e115-457c-9fbe-19b9da21626b">
                     <id root="7d12060b-0dfb-4a3e-b195-ea87b9cf22bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Perioperative Prophylaxis </title>
                     <text>
                        <paragraph>Cefazolin for Injection is indicated for perioperative prophylaxis in adult patients <content styleCode="italics">[see Dosage and Administration (2.1, 2.2, 2.3, 2.4)</content>.</paragraph>
                        <paragraph>The perioperative use of Cefazolin for Injection is indicated in adult surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty).</paragraph>
                        <paragraph>The prophylactic administration of Cefazolin for Injection preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for B. Braun Medical’s Cefazolin for Injection and Dextrose for Injection. However, due to B. Braun Medical’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_63caa1cf-b52b-428a-90ce-6757a57e1898">
                     <id root="c1dd6f54-fcd7-4dfa-8d1e-b64bc643f3e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Usage  </title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection USP and other antibacterial drugs, Cefazolin for Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6180128f-94ff-4b5b-b7fa-b5f83136b532">
               <id root="f92eabdd-882f-4aa4-b326-400c1e812a5c"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20240329"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>For intravenous infusion only administered over approximately 30 minutes. (2.1)</item>
                           <item>
                              <caption>•</caption>Not for intravenous bolus administration or intramuscular administration. (2.1)</item>
                        </list>
                        <table width="100%">
                           <col width="16%"/>
                           <col width="19%"/>
                           <col width="19%"/>
                           <tbody>
                              <tr styleCode="Toprule">
                                 <td colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Table 1: Recommended Dosage for Perioperative Prophylaxis in Adults with CLcr Equal to 55 mL/min or Greater (2.2)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Dose administered</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">½ hour to 1 hour prior to the start</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">of surgery</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Additional dose during lengthy operative procedures (e.g., 2 hours or more)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Dose for 24 hours postoperatively</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1 gram (g) to 2 g</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>500 mg to 1 g</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>500 mg to 1 g every 6 hours to 8 hours</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Dosage adjustment is required for adult patients with CLcr that is less than 55 mL/min. (2.3 and 8.6) </item>
                           <item>
                              <caption>•</caption>See full prescribing information for preparation and administration instructions. (2.4)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_eaeedace-ab6b-4861-801d-a244575843c2">
                     <id root="6b9c87ee-c73e-461a-be0a-a4df61ee25bc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration Instructions </title>
                     <text>
                        <paragraph>Administer Cefazolin for Injection via intravenous infusion only over approximately 30 minutes. <content styleCode="bold">Not</content> for intravenous bolus administration or intramuscular administration.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ff4d6e07-56aa-4c94-8073-b46ece8f197d">
                     <id root="bfb4d89a-7016-4aee-a793-d726c9c5c405"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage for Perioperative Prophylaxis  </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="underline">Dosage for Perioperative Prophylaxis in Adults with Creatinine Clearance (CLcr) Equal to 55 mL/min or Greater</content>
                           </item>
                           <item>
                              <caption> </caption>To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended dosages are described in Table 1 below.</item>
                        </list>
                        <table width="100%">
                           <col width="39%"/>
                           <col width="29%"/>
                           <col width="33%"/>
                           <tbody>
                              <tr styleCode="Toprule">
                                 <td colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Table 1: Recommended Dosage for Perioperative Prophylaxis in Adults with CLcr Equal to 55 mL/min or Greater </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dose administered</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">½ hour to 1 hour prior to the start</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">of surgery</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Additional dose during lengthy operative procedures (e.g., 2 hours or more)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dose for 24 hours postoperatively</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1 gram (g) to 2 g</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>500 mg to 1 g</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>500 mg to 1 g every 6 hours to 8 hours</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>It is important that (i) the preoperative dose be given just prior (1/2 hour to 1 hour) to the start of surgery so that adequate antibacterial concentrations are present in the serum and tissues at the time of initial surgical incision and (ii) cefazolin be administered, if necessary, at appropriate intervals during surgery to provide sufficient concentrations of the antibacterial drug at the anticipated moments of greatest exposure to infective organisms.</paragraph>
                        <paragraph>The perioperative prophylactic administration of cefazolin should usually be discontinued within a 24-hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of cefazolin may be continued for 3 to 5 days following the completion of surgery.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for B. Braun Medical’s Cefazolin for Injection and Dextrose for Injection. However, due to B. Braun Medical’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240329"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bc3737e3-7941-47d1-926a-bbac59c1227d">
                     <id root="a7aca467-e8e3-4bf2-842c-e98be6dcd32d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Preparation of Cefazolin for Injection </title>
                     <text>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter is evident in reconstituted fluids, the drug solutions should be discarded. Reconstituted solutions may range in color from pale yellow to yellow.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Reconstitution and Dilution</content>
                        </paragraph>
                        <paragraph>For intravenous infusion, reconstitute Cefazolin for Injection single-dose vials with Sterile Water for Injection according to Table 3 below and <content styleCode="italics">shake well</content>. After reconstitution further dilute according to Table 3 using the following diluents:</paragraph>
                        <paragraph>For intermittent or continuous infusion: Dilute reconstituted Cefazolin for Injection in one of the following solutions: </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>0.9% Sodium Chloride Injection, USP </item>
                           <item>
                              <caption>•</caption>5% Dextrose Injection, USP</item>
                        </list>
                        <paragraph>Discard unused portion.</paragraph>
                        <table width="100%">
                           <col width="15%"/>
                           <col width="21%"/>
                           <col width="19%"/>
                           <col width="19%"/>
                           <col width="26%"/>
                           <tbody>
                              <tr styleCode="Toprule">
                                 <td align="center" colspan="5" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Table 3: Volumes for Reconstitution and Dilution and Final Concentrations </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Cefazolin for Injection Vial Contents</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Amount of Sterile Water for Injection for Reconstitution</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Approximate Reconstituted Concentrations</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Recommended Diluent Volume</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Approximate Final Concentrations</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>2 grams</paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>5 mL</paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Lrule Toprule " valign="middle">
                                    <paragraph>317 mg/mL</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>50 mL </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>40 mg/mL </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>100 mL</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>20 mg/mL</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>3 grams</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>7.5 mL</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>319 mg/mL</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>100 mL</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>30 mg/mL</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Storage of Reconstituted and Diluted Solutions</content>
                        </paragraph>
                        <paragraph>When reconstituted or diluted according to the instructions above, Cefazolin for Injection is stable for 4 hours at room temperature or for 3 days if stored under refrigeration at 2°C to 8°C (36°F to 46°F).</paragraph>
                     </text>
                     <effectiveTime value="20240329"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_dc716172-a40f-47d0-bc44-7f6ae9a66ff6">
               <id root="b96ff0cc-41aa-4b9c-b481-c8f5de7f545c"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Cefazolin for Injection: Supplied as 2 grams or 3 grams of cefazolin as a white to cream powder in a single-dose vial for reconstitution. </paragraph>
               </text>
               <effectiveTime value="20240329"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>For Injection: 2 grams or 3 grams of cefazolin as a powder in a single-dose vial for reconstitution. (3)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_1349f404-0454-4867-8cf1-3b4bef8d6868">
               <id root="336445ae-68b4-4843-bbc1-a3d3c344e0a8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <effectiveTime value="20230518"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_6b4d9144-8dd1-406b-ba4a-e7d556505a86">
                     <id root="0148eed8-6e90-4d3e-ae75-ae762f71b7c3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Hypersensitivity to Cefazolin or the Cephalosporin Class of Antibacterial Drugs, Penicillins, or Other Beta-lactams </title>
                     <text>
                        <paragraph>Cefazolin for Injection is contraindicated in patients who have a history of immediate hypersensitivity reactions (e.g., anaphylaxis, serious skin reactions) to cefazolin or the cephalosporin class of antibacterial drugs, penicillins, or other beta-lactams <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_84028b07-ec5c-4863-897e-64332a30e1d1">
               <id root="45663f68-83bf-42b2-9700-9086c6f5e74f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20240329"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hypersensitivity Reactions: Cross-hypersensitivity may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction occurs, discontinue the drug. (5.1)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">
                                 <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea (CDAD)</content>: May range from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. (5.3) </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Prothrombin Activity</content>: May be associated with a fall in prothrombin activity. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_3a8e37bf-87b1-48a7-b2f1-1ebeca58a91f">
                     <id root="e7f19257-1cd0-4bb3-a2cc-4116ebd121c2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins, or Other Beta-lactams </title>
                     <text>
                        <paragraph>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before therapy with Cefazolin for Injection is instituted, careful inquiry should be made to determine whether the patient has had previous immediate hypersensitivity reactions to cefazolin, cephalosporins, penicillins, or carbapenems. Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to Cefazolin for Injection occurs, discontinue the drug.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_803bb3bc-77fd-436b-82de-5d26da06f1d7">
                     <id root="6b5bce1c-1203-4ebb-acba-499eae1e6c7d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Seizures in Patients with Renal Impairment </title>
                     <text>
                        <paragraph>Seizures may occur with the administration of Cefazolin for Injection, particularly in patients with renal impairment when the dosage is not reduced appropriately. Discontinue Cefazolin for Injection if seizures occur or make appropriate dosage adjustments in patients with renal impairment <content styleCode="italics">[see Dosage and Administration (2.3)]</content>. Anticonvulsant therapy should be continued in patients with known seizure disorders.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d3917bb7-63cb-4ccf-97d3-3e14bb521802">
                     <id root="aff72982-c32e-4df5-a94c-34367b67cf0e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="italics">5.3 Clostridioides difficile</content>-associated Diarrhea </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefazolin for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile </content>produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing isolates of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_245cbdfb-b143-4105-a716-c181f762a046">
                     <id root="665d73ec-b125-4383-b4da-fe7033f9c5b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Risk of Development of Drug-resistant Bacteria </title>
                     <text>
                        <paragraph>Prescribing Cefazolin for Injection in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                        <paragraph>As with other antimicrobials, prolonged use of Cefazolin for Injection may result in overgrowth of nonsusceptible microorganisms. Repeated evaluation of the patient's condition is essential. Should superinfection occur during therapy, appropriate measures should be taken.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_57f678e3-a8a2-4ec6-9ea1-38d5118867eb">
                     <id root="88b697d1-1dab-4913-a6bf-2a1f97311e2d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5 Prothrombin Activity</content>
                     </title>
                     <text>
                        <paragraph>Cefazolin for Injection may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated.</paragraph>
                     </text>
                     <effectiveTime value="20240329"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_87e451f0-6798-4e60-a602-a014f510ecd6">
                     <id root="0e6cb0fe-704d-434d-a9c6-8e32412e8c5b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Drug/Laboratory Test Interactions </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Urinary Glucose</content>
                           </content>
                        </paragraph>
                        <paragraph>The administration of cefazolin may result in a false-positive reaction with glucose in the urine when using glucose tests based on Benedict’s copper reduction reaction that determine the amount of reducing substances like glucose in the urine. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">Coombs’ Test</content>
                           </content>
                        </paragraph>
                        <paragraph>Positive direct Coombs' tests have been reported during treatment with cefazolin. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs' testing of newborns whose mothers have received cephalosporin antibacterial drugs before parturition, it should be recognized that a positive Coombs' test may be due to the drug.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_d145c248-405c-4764-bf5a-51cb25ba7cd5">
               <id root="247fc919-4732-404b-b6c5-db5ff9117b5b"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following serious adverse reactions to cefazolin for injection are described below and elsewhere in the labeling:</paragraph>
                  <paragraph>• Hypersensitivity Reactions to Cefazolin, Cephalosporins, Penicillins, or Other Beta-lactams <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>
                  </paragraph>
                  <paragraph>• Seizures in Patients with Renal Impairment <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                  </paragraph>
                  <paragraph>• <content styleCode="italics">Clostridioides difficile</content>-associated Diarrhea <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240329"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="ordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Adult Patients</content>: Most common adverse reactions: gastrointestinal (nausea, vomiting, diarrhea), and allergic reactions (anaphylaxis, urticaria, skin rash). (6)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">WG Critical Care, LLC at 1-866-562-4708</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_9692b900-6e48-4dd6-b198-4d14cb5a3f51">
                     <id root="7b9a7571-1d40-4075-9a62-a3e5547f9eeb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The following adverse reactions were reported from clinical trials:</paragraph>
                        <paragraph>Gastrointestinal: Diarrhea, oral candidiasis (oral thrush), mouth ulcers, vomiting, nausea, stomach cramps, epigastric pain, heartburn, flatus, anorexia and pseudomembranous colitis. Onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>.</paragraph>
                        <paragraph>Allergic: Anaphylaxis, eosinophilia, urticaria, itching, drug fever, skin rash, Stevens-Johnson syndrome.</paragraph>
                        <paragraph>Hematologic: Neutropenia, leukopenia, thrombocytopenia, thrombocythemia.</paragraph>
                        <paragraph>Hepatic: Transient rise in SGOT, SGPT, and alkaline phosphatase levels has been observed. Reports of hepatitis have been received.</paragraph>
                        <paragraph>Renal: Reports of increased BUN and creatinine levels, as well as renal failure, have been received.</paragraph>
                        <paragraph>Local Reactions: Instances of phlebitis have been reported at site of injection. Some induration has occurred.</paragraph>
                        <paragraph>Other Reactions: Pruritus (including genital, vulvar and anal pruritus, genital moniliasis, and vaginitis). Dizziness, fainting, lightheadedness, confusion, weakness, tiredness, hypotension, somnolence and headache.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for B. Braun Medical’s Cefazolin for Injection and Dextrose for Injection. However, due to B. Braun Medical’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f466a4e5-623a-4c64-b120-3d0f9d4a7be1">
                     <id root="b7ea055c-0ec8-4e1d-990d-8df365c3b772"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience  </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of cefazolin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorders: Serum sickness-like reaction</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and urinary disorders: Acute tubulointerstitial nephritis (ATIN)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders: Acute generalized exanthematous pustulosis (AGEP)</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6d732415-c466-44a4-bf09-c4198d4c39ac">
                     <id root="04067d35-dbc6-4cfa-89dc-bd58b4101ce7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.3 Cephalosporin-class Adverse Reactions </title>
                     <text>
                        <paragraph>In addition to the adverse reactions listed above that have been observed in patients treated with cefazolin, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterials: Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal impairment, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, a fall in prothrombin activity, hepatic impairment including cholestasis, and pancytopenia.</paragraph>
                     </text>
                     <effectiveTime value="20240329"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_78926722-056f-425a-b1a9-2608f92c4cbf">
               <id root="86a17ee6-d217-4de8-9927-887b3bda41a3"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <text>
                  <paragraph>The renal excretion of cefazolin is inhibited by probenecid. Co-administration of probenecid with Cefazolin for Injection is not recommended.</paragraph>
               </text>
               <effectiveTime value="20230518"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Probenecid: </content>The renal excretion of cefazolin is inhibited by probenecid. Co-administration of probenecid with Cefazolin for Injection is not recommended. (7)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_cd0dbc52-6780-4b65-bfdc-bbc94310ea78">
               <id root="2e47a784-4dd7-4b19-9f2d-ea9cf95244fb"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20240329"/>
               <component>
                  <section ID="ID_9a4e61a8-a37f-4b8c-b30a-dbfdb982f5d0">
                     <id root="a043e861-a31b-433b-86b4-77e7adc60af1"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data from published prospective cohort studies, case series and case reports over several decades with cephalosporin use, including cefazolin, in pregnant women have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Cefazolin crosses the placenta. </paragraph>
                        <paragraph>Animal reproduction studies with rats, mice and rabbits administered cefazolin during organogenesis at doses 1 to 3 times the maximum recommended human dose (MRHD) did not demonstrate adverse developmental outcomes. In rats subcutaneously administered cefazolin prior to delivery and throughout lactation, there were no adverse effects on offspring at a dose approximately 2 times the MRHD <content styleCode="italics">(see Data)</content>.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data </content>
                        </paragraph>
                        <paragraph>While available studies cannot definitively establish the absence of risk, published data from case-control studies and case reports over several decades have not identified an association with cephalosporin use during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph>Reproduction studies have been performed in rats, mice and rabbits administered cefazolin during organogenesis at doses of 2000, 4000 and 240 mg/kg/day (approximately 1 to 3 times the maximum recommended human dose on a body surface area comparison). There was no evidence of any adverse effects on embryofetal development due to cefazolin. In a peripostnatal study in rats, cefazolin administered subcutaneously up to 1200 mg/kg/day (approximately 2 times the MRHD based on body surface area comparison) to pregnant dams prior to delivery and through lactation caused no adverse effects on offspring.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8af24ce7-108e-4fed-9d14-ccd31c693e1c">
                     <id root="91d86fa4-b3d2-41c7-8432-fe76b20d01d7"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>Data from published literature report that cefazolin is present in human milk but is not expected to accumulate in a breastfed infant. There are no data on the effects of cefazolin on the breastfed child or on milk production. </paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cefazolin for Injection and any potential adverse effects on the breastfed child from Cefazolin for Injection or from the mother’s underlying condition.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_83b13365-731d-4863-8e2b-b8e0dc7ad94a">
                     <id root="63d9e528-4891-4788-940e-fbcb67e4ddd7"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Safety and effectiveness of Cefazolin for Injection for perioperative prophylaxis have not been established for pediatric patients less than 10 years or weighing less than 50 kg.</paragraph>
                        <paragraph>The safety and effectiveness of Cefazolin for Injection in premature infants and neonates have not been established and is not recommended for use in this age group of pediatric patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for B. Braun Medical’s Cefazolin for Injection and Dextrose for Injection. However, due to B. Braun Medical’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_233f9cd0-154e-4b74-9810-c6c22624ae21">
                     <id root="17393f6c-174e-4194-9f95-83fd4eb0ad82"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the 920 subjects who received cefazolin in clinical studies, 313 (34%) were 65 years and over, while 138 (15%) were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function <content styleCode="italics">[see Dosage and Administration (2.3) and Warnings and Precautions (5.2)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d91464ad-6e7e-45b4-8f63-cea10b72046d">
                     <id root="e5a25d8f-6970-467b-883c-d05918699b2e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment </title>
                     <text>
                        <paragraph>When Cefazolin for Injection is administered to adult patients with low urinary output because of impaired renal function (creatinine clearance less than 55 mL/min. for adult patients), lower daily dosage is required <content styleCode="italics">[see Dosage and Administration (2.3) and Warnings and Precautions (5.2)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240329"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_458a85d0-0895-49c7-a2bf-6ee76138661d">
               <id root="d9d490b3-3897-434d-9954-aad4f49f8701"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Accidental overdosage resulting in seizures may occur in patients with renal impairment who receive doses greater than the recommended dosage of Cefazolin for Injection <content styleCode="italics">[see Warnings and Precautions (5.2)]. </content>If seizures associated with accidental overdosage occur, discontinue Cefazolin for Injection and give supportive treatment.</paragraph>
               </text>
               <effectiveTime value="20230518"/>
            </section>
         </component>
         <component>
            <section ID="ID_f570f55b-97d7-4c12-b598-1d5a5a784a71">
               <id root="f781e6d3-8091-4029-b6ea-e25174c434fe"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Cefazolin for Injection USP is a semi-synthetic cephalosporin for parenteral administration. It is the sodium salt of 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]-methyl}-8-oxo-7-[2-(1<content styleCode="italics">H</content>-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo [4.2.0]oct‑2-ene-2-carboxylic acid.</paragraph>
                  <paragraph>Structural Formula:</paragraph>
                  <renderMultiMedia ID="id-353114211" referencedObject="ID_3ddfd4c5-bab2-44e7-a7e4-2c5d5109f9b3"/>
                  <paragraph>C<sub>14</sub>H<sub>13</sub>N<sub>8</sub>NaO<sub>4</sub>S<sub>3</sub>     M.W. 476.5</paragraph>
                  <paragraph>Cefazolin for Injection is supplied as a sterile powder in single-dose vials.</paragraph>
                  <paragraph>The 2 g/vial Cefazolin for Injection contains 2 grams of cefazolin (equivalent to 2.097 g of cefazolin sodium). The 3 g/vial Cefazolin for Injection contains 3 grams of cefazolin (equivalent to 3.144 grams of cefazolin sodium). </paragraph>
                  <paragraph>Each vial contains 48 mg of sodium per gram of cefazolin sodium.</paragraph>
                  <paragraph>After reconstitution with sterile water for injection, the drug product solution has a pH of 4.0 to 6.0.</paragraph>
                  <paragraph>Cefazolin for Injection is intended for intravenous infusion.</paragraph>
               </text>
               <effectiveTime value="20240329"/>
               <component>
                  <observationMedia ID="ID_3ddfd4c5-bab2-44e7-a7e4-2c5d5109f9b3">
                     <text>structural formula cefazolin</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_747298b7-f215-4f7d-9446-d869badbdda3">
               <id root="11b190e1-bbd7-40a1-a8fe-912efb4df0ee"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20230518"/>
               <component>
                  <section ID="ID_41aa67ce-3bf3-491b-a501-c6493b1e3583">
                     <id root="df469c51-383f-4e77-aaf8-c81658250c15"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Cefazolin is an antibacterial drug <content styleCode="italics">[see Microbiology (12.4)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f80d2233-032b-4a7f-a6da-59975a69da56">
                     <id root="cfaea543-cedf-4ec2-aed0-08e7686e975d"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>The pharmacokinetic/pharmacodynamic relationship for cefazolin has not been evaluated in patients.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0e9aea41-c9a4-4fd2-ae4d-d41e6f37239d">
                     <id root="b02ffbb6-186e-4cf5-9600-46375c82e0aa"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Studies have shown that following intravenous administration of cefazolin to normal volunteers, mean serum concentrations peaked at approximately 185 mcg/mL and were approximately 4 mcg/mL at 8 hours for a 1 gram dose. </paragraph>
                        <paragraph>In a study of constant intravenous infusion with dosages of 3.5 mg/kg for 1 hour (approximately 250 mg) and 1.5 mg/kg the next 2 hours (approximately 100 mg) in healthy volunteers, cefazolin serum concentrations at the third hour were approximately 28 mcg/mL.</paragraph>
                        <paragraph>Plasma pharmacokinetic parameters of cefazolin in healthy volunteers (N=12) following a single 15-minute IV infusion of 2 grams of Cefazolin for Injection are summarized in Table 4.</paragraph>
                        <table width="549.9pt">
                           <col width="21%"/>
                           <col width="8%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <col width="13%"/>
                           <col width="11%"/>
                           <col width="11%"/>
                           <col width="11%"/>
                           <tbody>
                              <tr styleCode="Toprule">
                                 <td colspan="8" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Table 4: Mean (Standard Deviation) Plasma Pharmacokinetic Parameters of Cefazolin in Healthy Volunteers </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top"/>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">N </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Cmax (mcg/mL) </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Tmax*</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(h) </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">AUC0-inf (mcg*h/mL) </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">t1/2 </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(h) </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">CL (L/h) </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Vz (L) </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Single 2 grams Dose as a 15-Minute IV Infusion </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>12 </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>280.9 (45.9) </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>0.25</paragraph>
                                    <paragraph>(0.25-0.33) </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>509.9 (89.3) </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>2.01 (0.28) </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>4.03 (0.68) </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>11.50 (1.53) </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*Tmax reported as median (range)</paragraph>
                        <paragraph>N= number of subjects observed; Cmax = maximum plasma concentration; Tmax = time to maximum plasma concentration; AUC0-inf = area under the plasma concentration-time curve extrapolated to infinity; t1/2 = apparent plasma terminal elimination half-life; CL = total clearance; Vz = volume of distribution</paragraph>
                        <paragraph>Studies in patients hospitalized with infections indicate that cefazolin produces mean peak serum concentrations approximately equivalent to those seen in normal volunteers.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Distribution</content>
                        </paragraph>
                        <paragraph>Bile concentrations in patients without obstructive biliary disease can reach or exceed serum concentrations by up to five times; however, in patients with obstructive biliary disease, bile concentrations of cefazolin are considerably lower than serum concentrations (less than 1 mcg/mL).</paragraph>
                        <paragraph>In synovial fluid, the cefazolin concentration becomes comparable to that reached in serum at about 4 hours after drug administration.</paragraph>
                        <paragraph>Studies of cord blood show prompt transfer of cefazolin across the placenta. Cefazolin is present in very low concentrations in the milk of nursing mothers.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Elimination</content>
                        </paragraph>
                        <paragraph>The serum half-life for cefazolin is approximately 1.8 hours following IV administration.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Cefazolin is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for B. Braun Medical’s Cefazolin for Injection and Dextrose for Injection. However, due to B. Braun Medical’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4a2a099f-03a1-475e-8af7-a11784e31e6c">
                     <id root="27059623-2c37-4d0d-a484-14e6b20c1c0a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.4 Microbiology </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Mechanism of Action</content>
                           </content>
                        </paragraph>
                        <paragraph>Cefazolin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Resistance</content>
                           </content>
                        </paragraph>
                        <paragraph>Predominant mechanisms of bacterial resistance to cephalosporins include the presence of extended-spectrum beta-lactamases and enzymatic hydrolysis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                        </paragraph>
                        <paragraph>Cefazolin has been shown to be active against most isolates of the following microorganisms, both <content styleCode="italics">in vitro </content>and in clinical infections [<content styleCode="italics">see Indications and Usage (1)</content>]:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Aerobic bacteria</content>
                        </paragraph>
                        <paragraph>Gram-Positive Bacteria</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Staphylococcus aureus</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Staphylococcus epidermidis</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Streptococcus agalactiae</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Streptococcus pneumoniae</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Streptococcus pyogenes</content>
                           </item>
                        </list>
                        <paragraph>Methicillin-resistant staphylococci are uniformly resistant to cefazolin.</paragraph>
                        <paragraph>Gram-Negative Bacteria</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Escherichia coli</content>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="italics">Proteus mirabilis</content>
                           </item>
                        </list>
                        <paragraph>Most isolates of indole positive Proteus (<content styleCode="italics">Proteus vulgaris</content>), <content styleCode="italics">Enterobacter </content>spp., <content styleCode="italics">Morganella morganii, Providencia rettgeri, Serratia </content>spp., and <content styleCode="italics">Pseudomonas </content>spp. are resistant to cefazolin.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Susceptibility Testing</content>
                           </content>
                        </paragraph>
                        <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: <linkHtml href="https://www.fda.gov/STIC">https://www.fda.gov/STIC</linkHtml>.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_be74388e-cf75-4e68-b018-3f9f2eb202e7">
               <id root="0524bcce-5609-425e-9470-9b6db97cedaa"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20230518"/>
               <component>
                  <section ID="ID_78f59ed4-7505-4454-9289-2a2b34483487">
                     <id root="767b6d82-85e5-4fe6-94d4-c29738023112"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis and Mutagenesis </content>
                        </paragraph>
                        <paragraph>Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of Cefazolin for Injection have not been performed.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Fertility studies conducted in rats subcutaneously administered cefazolin at doses of 2000 mg/kg/day (approximately 3 times the maximum recommended human dose based on body surface area comparison) showed no impairment of mating and fertility.</paragraph>
                     </text>
                     <effectiveTime value="20230518"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_0d421c73-4e32-4e24-9960-208b069a7a1a">
               <id root="b8355b57-a770-4d20-8ffd-4246aaa74d9c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Cefazolin for Injection is available in a single-dose vial containing 2 grams or 3 grams of cefazolin as a white to cream powder for reconstitution. Each vial contains cefazolin sodium equivalent to 2 grams or 3 grams of cefazolin, and is supplied as follows:</paragraph>
                  <paragraph>2 grams per Single-Dose Vial:	NDC 44567-840-01</paragraph>
                  <paragraph>Carton of 25:	NDC 44567-840-25</paragraph>
                  <paragraph>3 grams per Single-Dose Vial:	NDC 44567-845-01</paragraph>
                  <paragraph>Carton of 25:	NDC 44567-845-25</paragraph>
                  <paragraph>Store Cefazolin for Injection vials at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Protect from Light. </paragraph>
                  <paragraph>Storage conditions for the reconstituted and diluted solutions are described elsewhere in labeling <content styleCode="italics">[see Dosage and Administration (2.4)].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240329"/>
            </section>
         </component>
         <component>
            <section ID="ID_9974aa38-8f9d-4ae3-91b9-8602b922ce20">
               <id root="1f860091-b15e-458d-9abc-3222c90da1d6"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Serious Allergic Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that allergic reactions, including serious allergic reactions could occur and that serious reactions require immediate treatment and discontinuation of Cefazolin for Injection. Patients should report to their health care provider any previous allergic reactions to cefazolin, cephalosporins, penicillins, or other similar antibacterials <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Seizures</content>
                  </paragraph>
                  <paragraph>Advise patients that seizures could occur with Cefazolin for Injection. Instruct patients to inform a healthcare provider at once of any signs and symptoms of seizures, for immediate treatment, dosage adjustment, or discontinuation of Cefazolin for Injection <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Diarrhea </content>
                  </paragraph>
                  <paragraph>Advise patients that diarrhea is a common problem caused by antibacterials including cefazolin for injection, which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, including Cefazolin for Injection, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterials. If this occurs, patients should contact a physician as soon as possible <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Antibacterial Resistance </content>
                  </paragraph>
                  <paragraph>Patients should be counseled that antibacterial drugs, including Cefazolin for Injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cefazolin for Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefazolin for Injection or other antibacterial drugs in the future <content styleCode="italics">[see Warnings and Precautions (5.4)]</content>.</paragraph>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>
                     <content styleCode="bold">WG Critical Care, LLC</content>
                  </paragraph>
                  <paragraph>Paramus, NJ 07652</paragraph>
                  <paragraph>Made in Italy</paragraph>
               </text>
               <effectiveTime value="20230518"/>
            </section>
         </component>
         <component>
            <section ID="ID_f02712a8-c11c-4ff9-b53b-cc158549b86b">
               <id root="e4427fca-2af4-4b66-9635-676f14cd40a2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <paragraph>NDC 44567-840-01</paragraph>
                  <paragraph>Cefazolin for Injection, USP 2 grams per vial</paragraph>
                  <paragraph>For Intravenous Infusion Only.</paragraph>
                  <renderMultiMedia ID="id1692648076" referencedObject="ID_4bcd1584-e085-4a72-bce9-8f0915dd2a37"/>
               </text>
               <effectiveTime value="20240331"/>
               <component>
                  <observationMedia ID="ID_4bcd1584-e085-4a72-bce9-8f0915dd2a37">
                     <text>Cefazolin 2 g vial label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f59b70f2-e642-4267-9f2d-c9c5a4de1dc6">
               <id root="77ddc811-a5ff-4a54-8106-783df3c22eb8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <paragraph>NDC 44567-845-01</paragraph>
                  <paragraph>Cefazolin for Injection, USP 3 grams per vial</paragraph>
                  <paragraph>For Intravenous Infusion Only.</paragraph>
                  <renderMultiMedia ID="id350234084" referencedObject="ID_033cf87f-0e5e-49b0-a0cf-3ec8151dad77"/>
               </text>
               <effectiveTime value="20240331"/>
               <component>
                  <observationMedia ID="ID_033cf87f-0e5e-49b0-a0cf-3ec8151dad77">
                     <text>Cefazolin 3 g vial label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>